CLU and prostate carcinoma: Combined with other chemotherapeutic agents, antisense compounds targeting APOJ proved successful in clinical trials for the treatment of prostate cancer.91, 92 Expression of APOJ protein correlated with Gleason scores in prostate cancer.93 APOJ was also overexpressed in HCC tissues, which corresponded to higher TNM stages and inferior histological grade.94 Overexpression of APOJ promoted epithelial‐mesenchymal transition and migration of HCC in vitro and promoted metastasis in vivo.95 Silencing the APOJ gene enhanced the chemosensitivity of hepatic carcinoma cells.96